TLDR CME Group will launch Cardano, Chainlink, and Stellar futures on February 9. The new contracts will be available in both standard and micro versions. TheseTLDR CME Group will launch Cardano, Chainlink, and Stellar futures on February 9. The new contracts will be available in both standard and micro versions. These

CME Group Adds Cardano, Chainlink, and Stellar to Crypto Futures

TLDR

  • CME Group will launch Cardano, Chainlink, and Stellar futures on February 9.
  • The new contracts will be available in both standard and micro versions.
  • These additions expand CME Group’s existing crypto derivatives offering.
  • CME Group aims to provide regulated products to meet growing institutional demand.
  • The launch reflects CME’s ongoing effort to diversify its crypto market offerings.

CME Group is expanding its crypto derivatives offering with new futures tied to Cardano, Chainlink, and Stellar. The company will launch these contracts on February 9, including both standard and micro versions. This move follows the exchange’s aim to diversify its crypto suite, which already includes bitcoin, ether, XRP, and Solana futures.

Cardano Futures Launch at CME Group

CME Group will begin offering Cardano futures in both standard and micro contracts starting February 9. These contracts will allow traders to take positions in ADA, one of the leading cryptocurrencies in terms of market cap. The micro contracts will cater to those looking for smaller positions at a lower cost, while standard contracts will offer larger exposure.

CME Group aims to broaden access to Cardano for its institutional clients. According to Giovanni Vicioso, CME’s global head of cryptocurrency products, “Clients are looking for trusted, regulated products to manage price risk.” This expansion highlights the growing interest in Cardano within regulated markets and underscores CME’s effort to provide more diverse options for crypto traders.

Alongside Cardano, CME Group will also introduce Chainlink (LINK) futures in early February. This marks another key addition to the growing roster of crypto derivatives available on CME’s platform. With the introduction of Chainlink futures, CME Group continues to meet demand for decentralized oracle services in crypto markets, which have become integral to the DeFi ecosystem.

By adding Chainlink to its crypto derivatives lineup, CME Group is responding to the increasing institutional interest in the token’s utility. The new futures contracts will provide traders with regulated instruments to manage price risk in Chainlink, offering both standard and micro contract sizes for different risk profiles.

CME Enhances Crypto Derivatives with Stellar

Stellar’s XLM will also be part of CME’s expanding derivatives offering. As with Cardano and Chainlink, CME will provide both standard and micro futures contracts for Stellar starting February 9. This expansion reflects CME Group’s continued focus on adding popular digital assets to its platform to cater to the needs of institutional clients.

The inclusion of Stellar futures will enhance the variety of crypto assets available for regulated trading. CME’s move underscores the exchange’s strategy of offering a diverse range of digital assets, helping institutional traders gain exposure to multiple blockchain projects with reliable, regulated contracts.

CME Group has made significant strides in the crypto derivatives space, establishing itself as a leader in offering regulated products for digital assets. The expansion to include Cardano, Chainlink, and Stellar futures is a part of the company’s broader strategy to meet growing demand for trusted crypto derivatives.

The post CME Group Adds Cardano, Chainlink, and Stellar to Crypto Futures appeared first on CoinCentral.

Market Opportunity
Micro GPT Logo
Micro GPT Price(MICRO)
$0.000183
$0.000183$0.000183
-2.65%
USD
Micro GPT (MICRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26